The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
VERZENIO (Eli Lilly Australia Pty Ltd)
Product name
VERZENIO
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
252 (255 working days)
Active ingredients
abemaciclib
Registration type
EOI
Indication
Early Breast Cancer
VERZENIO (tablet) in combination with endocrine therapy is now also indicated for the adjuvant treatment of patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative, node-positive early breast cancer at high risk of recurrence.
In pre- or peri-menopausal women, endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.